AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too on May 18, 2026 aldosterone synthase inhibitor approval sweetener AstraZeneca baxdrostat Baxfendy benralizumab Dentatorubral-Pallidoluysian Atrophy Fasenra Hypertensive disease United States Food and Drug Administration +